# IMI 10th Anniversary Scientific Symposium

## Agenda

### Day 1

22.10.2018 • Crowne Plaza Le Palace • Rue Gineste 3 • 1210 Brussels • Belgium

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 09:00</td>
<td>Registration &amp; welcome coffee</td>
</tr>
<tr>
<td>09:00 – 10:00</td>
<td><strong>Opening session</strong></td>
</tr>
<tr>
<td></td>
<td>Pierre Meulien, Executive Director, IMI</td>
</tr>
<tr>
<td></td>
<td>Jean-Christophe Tellier, Chief Executive Officer and Chairman of the Executive Committee, UCB</td>
</tr>
<tr>
<td></td>
<td>Jonathan Knowles, Professor, Founding Chairman of IMI Board</td>
</tr>
<tr>
<td>10:00 – 11:00</td>
<td><strong>Stratification towards personalised medicines</strong></td>
</tr>
<tr>
<td>10:00 – 10:15</td>
<td>Setting the scene</td>
</tr>
<tr>
<td></td>
<td>Pierre Meulien, Executive Director, IMI</td>
</tr>
<tr>
<td>10:15 – 11:00</td>
<td>Presentation of key achievements from IMI projects</td>
</tr>
<tr>
<td></td>
<td><strong>Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer's Disease and Reconstruction of Relevant Mechanisms</strong></td>
</tr>
<tr>
<td></td>
<td>AETIONOMY - Holger Fröhlich, UCB</td>
</tr>
<tr>
<td></td>
<td><strong>Quantitative PET Imaging - From Research to Clinical Use</strong></td>
</tr>
<tr>
<td></td>
<td>AMYPAD - Fiona Heeman, VU University medical centre</td>
</tr>
<tr>
<td></td>
<td><strong>Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: A showcase from the epidemiological studies within the IMI DIRECT Consortium</strong></td>
</tr>
<tr>
<td></td>
<td>DIRECT - Robert Koivula, University of Oxford</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11:30 – 12:15</td>
<td>Presentation of key achievements from IMI projects</td>
</tr>
<tr>
<td></td>
<td><strong>Predicting Cognitive Decline through Structural MRI biomarkers: Results from the EMIF-AD Biomarker Discovery Study</strong></td>
</tr>
<tr>
<td></td>
<td>EPAD - Silvia Ingala, VU Medical Center</td>
</tr>
<tr>
<td></td>
<td><strong>The EU-AIMS Longitudinal European Autism Project: Examples of novel approaches to biomarker discovery</strong></td>
</tr>
<tr>
<td></td>
<td>EU-AIMS - Stefan Holiga, F. Hoffmann-La Roche &amp; Eva Loth, King’s College London</td>
</tr>
<tr>
<td></td>
<td><strong>Biomarker methods to enable stratification of patient populations in clinical trials for neuropathic pain</strong></td>
</tr>
<tr>
<td></td>
<td>EUROPAIN - Jan Vollert, Imperial College London</td>
</tr>
</tbody>
</table>
“Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors”
Onco Track - Moritz Schütte, Alacris Theranostics GmbH

“Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression”
PRECISESADS - Daniel Toro, GENYO

12:15 – 13:30 Lunch

13:30 – 14:00 Presentation of key achievements from IMI projects
- “Federating clinical data for biomedical research in type 2 diabetes”
  RHAPSODY - Thomas Sparsø, Novo Nordisk
- “Building handprints of complex diseases – severe asthma as a proof of concept”
  U-BIOPEPRED and eTRIKS - Bertrand De Meulder, European Institute for Systems Biology and Medicine

14:00 – 14:30 Panel discussion:
- Pamela Tenaerts, Executive Director, Clinical Trial Transformation Initiative
- Raj Long, Deputy Director - Integrated Development, Global Health, Bill & Melinda Gates Foundation
- Martin Hofmann-Apitalus, Head of the Department of Bioinformatics, Fraunhofer SCAI
- Maria Beatriz Da Silva Lima, Professor of Pharmacology and Pharmacotoxicology, Lisbon University

14:30 – 15:00 Coffee break

15:00 – 17:15 Patient centric approaches in drug development

15:00 – 15:15 Setting the scene
- Virginie Hivert, Therapeutic Development Director, EURORDIS

15:15 – 16:45 Presentation of key achievements from IMI projects
- “Patient involvement in the IMI-APPROACH project: invaluable insights and key ingredients”
  APPROACH - Leonie Hussaarts, Lygature & Jane Taylor
- “Patient education is a prerequisite for meaningful patient engagement in the life cycle of medicines”
  EUPATI - Tamás Bereczky, Eupati
- “Driving the use of Real World Evidence in healthcare decision making”
  GETREAL - Amr Makady, Zorginstituut Nederland
- “When to consider patient preference information along the medical product lifecycle? An overview of decision points and situations”
  PREFER - Chiara Whichello and Eline van Overbeeke, KU Leuven
“From development to labelling claim”  
PRO-active - Heleen Demeyer, Uz Gasthuisberg

“Baseline characteristics of participants of the SPRINTT randomised clinical trial”  
SPRINTT - Riccardo Calvani, Università Cattolica del Sacro Cuore

16:45 – 17:15 Panel discussion:
- Virginie Hivert, Therapeutic Development Director, EURORDIS
- Mary Baker, President, European Brain Council
- Fernand Sauer, Member, Académie National de Pharmacie
- Olivier Arnaud, Senior Director, European Research JDRF

17:15 – 19:15 Poster session

18:00 – 22:00 Networking cocktail
Agenda
Day 2
23.10.18

23.10.2018 • Crowne Plaza Le Palace • Rue Gineste 3 • 1210 Brussels • Belgium

08:30 – 09:00 Registration & welcome coffee

09:00 – 09:15 Introduction

Pierre Meulien, Executive Director, IMI

09:15 – 11:15 Enablers for discovery and development of new drugs

09:15 – 09:30 Setting the scene
- Jan Egebjerg, Senior Director, Neurodegeneration Discovery Biology, Janssen

09:30 – 11:15 Presentation of key achievements from IMI projects
- “An iPSC technology development collaboration – a critical component to enable ADAPTED”
  ADAPTED - Peter Reinhardt, AbbVie & Benjamin Schmid, Bioneer
- “Exploring the potential of lipidoid-polymer hybrid nanoparticles to deliver oligonucleotides to intracellular pharmacological targets”
  COMPACT - Thanki Kaushik, University of Copenhagen
- “Supporting stem cell research with modern data management technologies”
  EBISC - Stefanie Seltmann, Charité Berlin
- “EMIF Catalogue – the bridge between data custodians and biomedical researchers”
  EMIF - Alina Trifan, University of Aveiro
- “HARMONY Platform: using Big Data to fight blood cancers”
  HARMONY - Maria Abáigar-Alvarado, Institute of Biomedical Research of Salamanca
- “Supersaturation as driving force for intestinal absorption resulting in an increased oral bioavailability: case example with posaconazole”
  ORBITO - Bart Hens, KU Leuven
- “Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): Study protocol”
  RADAR-CNS - Faith Matcham, King’s College London
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 11:45</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11:45 – 12:15</td>
<td>Panel discussion:</td>
</tr>
<tr>
<td></td>
<td>▪ Jan Egebjerg, Senior Director, Neurodegeneration Discovery Biology,</td>
</tr>
<tr>
<td></td>
<td>Janssen</td>
</tr>
<tr>
<td></td>
<td>▪ Stefan Jaroch, Head External Innovation Technologies, R&amp;D</td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals, Bayer AG</td>
</tr>
<tr>
<td></td>
<td>▪ Magali Haas, CEO &amp; President, Cohen Veterans Bioscience</td>
</tr>
<tr>
<td></td>
<td>▪ Heiko Zimmermann, Head of Institute, Fraunhofer-Institut für</td>
</tr>
<tr>
<td></td>
<td>Biomedizinische Technik IBMT</td>
</tr>
<tr>
<td></td>
<td>▪ Hans-Georg Eichler, Senior medical officer, European Medicines</td>
</tr>
<tr>
<td></td>
<td>Agency</td>
</tr>
<tr>
<td>12:15 – 13:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:30 – 15:30</td>
<td>Collaborating to fight infections</td>
</tr>
<tr>
<td>13:30 – 13:45</td>
<td>Setting the scene</td>
</tr>
<tr>
<td></td>
<td>▪ Rino Rappuoli, Chief Scientist &amp; Head of External Research and</td>
</tr>
<tr>
<td></td>
<td>Development, GlaxoSmithKline</td>
</tr>
<tr>
<td>13:45 – 15:00</td>
<td>Presentation of key achievements from IMI projects</td>
</tr>
<tr>
<td></td>
<td>▪ “EURECA - Substudy of infections due to carbapenem-resistant</td>
</tr>
<tr>
<td></td>
<td>Enterobacteriaceae (CRE) along Europe. Inside COMBACTE network;</td>
</tr>
<tr>
<td></td>
<td>global information for a global problem”</td>
</tr>
<tr>
<td></td>
<td>COMBACTE-CARE - Maria Paniagua, Hospital Universitario Virgen</td>
</tr>
<tr>
<td></td>
<td>Macarena</td>
</tr>
<tr>
<td></td>
<td>▪ “A new European network for influenza vaccine effectiveness studies”</td>
</tr>
<tr>
<td></td>
<td>DRIVE - Topi Turunen, FISABIO</td>
</tr>
<tr>
<td></td>
<td>▪ “Field validation of novel diagnostic tools for Ebola virus detection in Sierra Leone”</td>
</tr>
<tr>
<td></td>
<td>EbolaMoDRAD - Colavita Francesca, INMI</td>
</tr>
<tr>
<td></td>
<td>▪ “Modelling the humoral immune response to Ebola vaccine”</td>
</tr>
<tr>
<td></td>
<td>EBOVAC1 - Irene Balelli, Inserm</td>
</tr>
<tr>
<td></td>
<td>▪ “Highly potent heavy chain only antibodies protect against MERS-CoV infection”</td>
</tr>
<tr>
<td></td>
<td>ZAPI - Nisreen Okba, Erasmus Medical Center</td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Panel discussion:</td>
</tr>
<tr>
<td></td>
<td>▪ Rino Rappuoli, Chief Scientist &amp; Head of External Research and</td>
</tr>
<tr>
<td></td>
<td>Development, GlaxoSmithKline</td>
</tr>
<tr>
<td></td>
<td>▪ Raj Long, Deputy Director - Integrated Development, Global Health,</td>
</tr>
<tr>
<td></td>
<td>Bill &amp; Melinda Gates Foundation</td>
</tr>
<tr>
<td></td>
<td>▪ Seamus O’Brien, R&amp;D Director, Global Antibiotic Research and</td>
</tr>
<tr>
<td></td>
<td>Development Partnership (GARDP)</td>
</tr>
<tr>
<td></td>
<td>▪ Isabelle Bekeredjian-Ding, Head of the Department of Microbiology,</td>
</tr>
<tr>
<td></td>
<td>Paul-Ehrlich-Institut</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16:00 – 17:00</td>
<td>Closing &amp; Prize ceremony</td>
</tr>
</tbody>
</table>
New targets, tools and pathways

1. “Support Translation Research with High Quality Data and Interactive Visual-analytics”
eTRIKS - Kavita Rege, University of Luxembourg

2. “Developing a robust evidence base on RSV disease and economic burden using a multi-disciplinary approach”
RESCEU - Rachel Reeves, the University of Edinburgh

3. “AMYPAD Diagnostic and Patient Management Study (AMYPAD-DPMS): rationale and study design”
AMYPAD - Daniele Altomare, IRCCS Fatebenefratelli

4. “Network-based modeling of APAP-induced hepatotoxicity using interactomics and transcriptomics data”
TransQST - Emre Guney, GRIB - IMIM / UPF

5. “Stroke Risk, Bleeding Risk and Anticoagulation in Hospital EHRs”
Big data @ heart - Daniel Bean, King’s College London & HDR UK

6. “DPP6 as a new biomarker suitable for human islet in vivo imaging”
INNODIA - Stéphane Demine, ULB Center for Diabetes Research

7. “Identification of Stratified Social-Behavioural Markers in Neuropsychiatric Disorders by using smartphone technology”
PRISM - Niels Jongs, Rijksuniversiteit Groningen

8. “Drug Evaluation in Guinea Pig Model”
PreDiCT TB - Faye Lanni, Public Health England

APPROACH - Eefje Van Helvoort, University Medical Centre Utrecht

10. “In vivo models of Drug-induced interstitial lung disease; tools to study and improve drug safety”
TRISTAN - Irma Mahmutovic Persson, Lund University

11. “RNA-sequencing of medulloblastoma patient-derived orthotopic xenograft models enables identification of both tumor and microenvironment specific biomarkers”
ITCC-P4 - Natalie Jäger, DKFZ and KITZ, Heidelberg
12. “Molecular characterization of patient-derived orthotopic xenograft models of paediatric brain tumours”
   ITCC-P4 - Sebastian Brabetz, Hopp Children’s Cancer Center at the NCT Heidelberg (KITZ)

13. “Candidate genes and pathways from ADAPTED Stage I integrative analysis”
   ADAPTED - Laura Madrid Márquez, CAEBi Bioinformatica

14. “Increased understanding of AD pathophysiology through novel cerebrospinal fluid markers: results from the EMIF-AD Multimodal Biomarker Discovery study”
   EMIF-AD - Isabelle Bos, Maastricht University

15. “Data analytics and bioinformatics to successfully define asthma subphenotypes”
   U-BIOPRED - Stelios Pavlidis, Data Science Institute, Imperial College London

16. “Collaborative capacity building: Creating new knowledge, new tools, new collaborative ties and educating young scientist”
   K4DD - Tale Sliedrecht, Lygature

17. “Developing a mechanism-based taxonomy of Alzheimer’s and Parkinson’s disease”
   AETIONOMY - Sepehr Golriz Khatami, Fraunhofer SCAI

18. “Proteome analyses in colorectal carcinoma reveals major protein alterations upon cancer development and metastasis”
   OncoTrack - Alireza Azimi, Uppsala University

   NGN-PET - Lucia Rutigliano, Axxam

20. “A new way to monitor Multiple Sclerosis”
   RADAR-CNS - Matteo Martinis, San Raffaele Hospital

   IMIDIA - Lara Bellini, Université Paris Diderot

22. “Glucagon and gastrointestinal hormones changes after Roux-en-Y gastric bypass: an IMI DIRECT study”
   DIRECT - Francesca Frau, Sanofi

23. “Application and optimization of Monocyte Activation Test for testing Tick Borne Encephalitis virus vaccine pyrogenicity”
   VAC2VAC - Marilena Paola Etna, Instituto Superiore di Sanità

24. “Development of Rift Valley fever virus neutralizing antibodies using bacterial superglues”
   ZAPI - Paul Wichgers Schreur, Wageningen Bioveterinary Research
25. “Interim Pharmacokinetic Analysis from the EVADE Phase 2 Clinical Trial of MEDI3902, a Bispecific Monoclonal Antibody Against PcrV and Psl of Pseudomonas aeruginosa”
   COMBACTE-MAGNET - Ana Catalina Hernandez, Centre Hospitalier Universitaire de Limoges

26. “Interim Pharmacokinetic Analysis from the SAATELLITE Phase 2 Clinical Trial of MEDI4893, an Extended Half-life Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin”
   COMBACTE-NET - Ana Catalina Hernandez, Centre Hospitalier Universitaire de Limoges

27. “Urinary metabolites as potential biomarkers of P. aeruginosa ventilator-associated pneumonia”
   RAPP-ID - Bart Jongers, University of Antwerp

28. “Laboratory Analysis workflows within the ASPIRE-ICU study”
   COMBACTE-NET and COMBACTE-MAGNET - Leen Timbermont, University of Antwerp

29. “New bio-informatic approach for the analysis of flow cytometry data”
   PRECISESADS - Lucas Le Lann, University of Brest

30. “Zebrafish Proteinopathy Models for Target Validation”
    IMPRIND - Jeffrey Hubbard, Institut de Recherches Servier

31. “New candidate genes in insulin target tissues: Elovl2 as a protective enzyme against glycaemic deterioration?”
    RHAPSODY - Justine Lallement, Université Paris Diderot

32. “Integration of models of drug-induced liver injury for risk assessment”
    Trans-QST and MIP-DILI - Rowena Sison-Young, University of Liverpool

33. “Isocyanide Chemistry (IMCR): Promising Technology For Future Drug Discovery And Development”
    ELF - Pravin Patil, University Of Groningen

34. “Developing human cellular phenotypic assays for pain”
    StemBANCC - Satyan Chintawar, University of Oxford

35. “Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells”
    OncoTrack - Joseph Regan, Charité - Universitätsmedizin Berlin

36. “A validated genetics-led system ‘Pi’ enables drug target discovery for immune traits”
    ULTRA-DD - Hai Fang, University Of Oxford

37. “Immunobridging approach to assess clinical benefit as the basis for licensure of the monovalent Ebola vaccine”
    EBOVAC 1 and 2 - Viki Bockstal, Janssen Vaccines & Prevention
38. “A Bordetella pertussis human challenge model induces immunising colonization in absence of symptoms”
   PERISCOPE - Hans de Graaf, University of Southampton

   eTRANSAFE – Ruud Bueters, Janssen

40. “In vitro antimicrobial activity of tobramycin, colistin, aztreonam and the new antibiotic POL7080 against cystic fibrosis Pseudomonas aeruginosa growing in biofilms”
   iABC - Maria Diez-Aguilar, Hospital Universitario Ramón y Cajal-IRyCIS

41. “Comparative assessment of seed extraction methods relevant for the study of Alzheimer disease”
   IMPRIND - Charlotte Delay, Janssen Pharmaceuticals

42. “Frequencies of cerebrospinal fluid ATN biomarker profiles and their association with memory function in persons without dementia”
   EMIF-AD - Olin Jansen, Maastricht University

From concept to trial

43. “Developing predictive in silico models for liver toxicity endpoints from in vivo histopathology data”
   eTOX - Kevin Pinto Gil, University Pompeu Fabra

44. “Prognostic factors and outcome of multiple myeloma patients enrolled in European clinical trials after a long-term follow-up. A pilot project by multiple myeloma community within HARMONY consortium”
   HARMONY - Mattia D’Agostino, University of Turin

45. “Alterning disease course before symptom onset: the European Prevention of Alzheimer’s Dementia (EPAD) project (WP4)”
   EPAD - Delia Gheorghe, University of Oxford

46. “COMBACTE LAB-Net, a European laboratory network for clinical trials on anti-infectives to combat bacterial resistance”
   COMBACTE-NET - Tomislav Kostyanev, University of Antwerp

47. “Tools to collect data on detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories part of the COMBACTE Laboratory network (LAB-Net)”
   COMBACTE-CARE and COMBACTE-NET - Tomislav Kostyanev, University of Antwerp

48. “Exploring MMN processing in Autism Spectrum Disorder during the odd-ball task: evidence from the EU-AIMS LEAP cohort”
   EU-AIMS - Jumana Ahmad, King’s College London
49. “Novel peptide vaccines against Rift valley fever virus”  
ZAPI - Benjamin Gutjahr, Friedrich-Loeffler-Institut FLI

50. “Identifying priority outcomes and understanding meaningful delay in disease progression for Alzheimer’s Disease across the spectrum”  
ROADMAP - Amanda Ly, University of Edinburgh

51. “Developmental changes in resting state power spectrum and functional connectivity in autism spectrum disorder”  
EU-AIMS - Pilar Garces, Roche

52. “Implementing a Phase II Ebola Vaccine Trial (EBOVAC2) in Burkina Faso”  
EBOVAC2 - Barry Houreratou, Centre MURAZ

53. “A systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals”  
EIQPD - Jan Vollert, Imperial College London

ELF - Laura Mariana Levy, Taros

ELF - Stanimira Hristeva, Taros

56. “Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination: an observational cohort study”  
EBOVAC & EBOPLUS - Francesco Santoro, University of Siena

57. “Transcriptomic analysis of the immune response to the rVSV-ZEBOV Ebola vaccine”  
VSV-EBOVAC - VSV-EBOPLUS - Francesco Santoro, University of Siena

New clinical and regulatory paradigms

58. “What is responsible antibiotic use? Towards a global definition”  
DRIVE-AB - Annelie Monnier, Radboud University Medical Center & Hasselt University

59. “The added value of quantitative amyloid PET in determining Alzheimer’s Disease (AD) dementia risk: the AMYPAD Prognostic and Natural History Study”  
AMYPAD - Isadora Lopes Alves, VU Medical Center Amsterdam

60. “Towards an adaptive mindset”  
ADAPT SMART - Solange Rohou, Astrazeneca

61. “Regulatory and HTA considerations for disease-modifying drugs in Alzheimer's disease”  
ROADMAP - Diana O'Rourke, National Institute for Health and Care Excellence (NICE)
62. “Time-to-event case-control designs: An efficacious tool for cohort studies on nosocomial infections when resources are limited”
   COMBACTE - Jan Feifel, Ulm University

63. “European Prevention of Alzheimer’s Dementia (EPAD) Registry for a longitudinal cohort and Alzheimer prevention trials”
   EPAD - Lisa Vermunt, VU University Medical Center

64. “Prioritisation and Intelligent Assessment of the Environmental Risks of Pharmaceuticals”
   iPIE - John Wilkinson, University of York

65. “Alignment of European regulatory and health technology assessments: a review of licensed products for Alzheimer’s Disease”
   ROADMAP - Marieke Dekker, Medicines Evaluation Board (MEB-CBG)

66. “IMI-PROTECT and benefit risk assessment”
   PROTECT - Edward Waddingham, Imperial College London

67. “Managing false-positive Ebola test results in the post-outbreak era: Experiences in the EBOVAC vaccine trial in rural Sierra Leone”
   EBOVAC - Frank Baiden, London School of Hygiene and Tropical Medicine

Patient engagement along the value chain

68. “Characterising and appraising patient preference exploration and elicitation methods”
   PREFER - Chiara Whichello, Erasmus University Rotterdam

69. “Prospective data collection on burden of RSV infection in Europe – paving the way for RSV vaccines and therapeutics”
   RESCEU - Joanne G. Wildenbeest, Wilhelmina Children’s Hospital, University Medical Center Utrecht

70. “Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes”
   PARADIGM - Chi Pakarinen, the Synergist

71. “Lessons learned in the recruitment of adolescents and children to the EBOVAC-Salone clinical trial in Sierra Leone”
   EBOVAC1 - Shona Lee, EBOVAC Salone, Social Science Team

72. “Bridging the gap between intention and action - Lessons learned from INNODIA’s Patient Advisory Committee”
   INNODIA - Jeannette Soderberg, JDRF